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s u m m a r y 
Background: Significant nosocomial transmission of SARS-CoV-2 has been demonstrated. Understanding 
the prevalence of SARS-CoV-2 carriage amongst HCWs at work is necessary to inform the development 
of HCW screening programmes to control nosocomial spread. 
Methods: Cross-sectional ‘snapshot’ survey from April-May 2020; HCWs recruited from six UK hospitals. 
Participants self-completed a health questionnaire and underwent a combined viral nose and throat swab, 
tested by Polymerase Chain Reaction (PCR) for SARS-CoV-2 with viral culture on majority of positive 
samples. 
Findings: Point prevalence of SARS-CoV-2 carriage across the sites was 2.0% (23/1152 participants), me- 
dian cycle threshold value 35.70 (IQR:32.42–37.57). 17 were previously symptomatic, two currently symp- 
tomatic (isolated anosmia and sore throat); the remainder declared no prior or current symptoms. Symp- 
toms in the past month were associated with threefold increased odds of testing positive (aOR 3.46, 95%CI 
1.38–8.67; p = 0.008). SARS-CoV-2 virus was isolated from only one (5%) of nineteen cultured samples. A 
large proportion (39%) of participants reported symptoms in the past month. 
Interpretation: The point-prevalence is similar to previous estimates for HCWs in April 2020, though 
a magnitude higher than in the general population. Based upon interpretation of symptom history and 
testing results including viral culture, the majority of those testing positive were unlikely to be infectious 
at time of sampling. Development of screening programmes must balance the potential to identify addi- 
tional cases based upon likely prevalence, expanding the symptoms list to encourage HCW testing, with 
resource implications and risks of excluding those unlikely to be infectious with positive tests. 
Funding: Public Health England. 
Crown Copyright © 2020 Published by Elsevier Ltd on behalf of The British Infection Association. All 
rights reserved. 
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l  terms ("novel coronavirus" OR "SARS-CoV-2 ′′ OR "COVID-19 ′′ 
OR “coronavirus”) AND ("workers" OR "staff") AND ("test- 
ing" OR "screening") from 31st December 2019 onwards 
with no other limits. This search was updated on 10th May 
2020, and in addition reference lists were checked and pre- 
print papers were shared with us through professional net- 
works. We found three papers commenting on prevalence 
of asymptomatic/pauci-symptomatic SARS-CoV-2 infection in 
healthcare workers, with prevalence estimates ranging from 
1.1 to 8%. One of these studies explored previous symptoms 
in depth, though this was based upon a retrospective ques- 
tionnaire and thus subject to recall bias. None of these stud- 
ies explored exposures to the SARS-CoV-2 virus, commented 
on whether participants had been tested prior to the start of 
the study, or broke down results by staff role. Only one re- 
ported on estimated viral load (as inferred from cycle thresh- 
old [Ct] value), and none reported attempting viral culture. 
Added value of this study 
This is the first published study of which we are aware 
that has been conducted across multiple sites in England 
and is therefore potentially more representative of the overall 
prevalence of SARS-CoV-2 infectivity amongst HCWs in the 
workplace. We explored symptoms in the preceding month 
in more depth than previous studies and in addition asked 
about previous test results and various exposures, also not 
commented on in other studies. Additionally, we attempted 
to isolate virus from some PCR-positive samples to look for 
evidence of infectious virus. 
Implications of all the available evidence 
Authors of previous studies have proposed that screen- 
ing asymptomatic HCWs for SARS-CoV-2 RNA may be bene- 
ficial, in addition to screening symptomatic HCWs. Our find- 
ings suggest that when prevalence of COVID-19 is very low, 
routine and repeated screening would be unlikely to have 
significant value, especially given the majority of participants 
testing positive in this study were unlikely to be infectious. 
However, in situations where prevalence levels are high in 
a particular population or setting, for example in a hospital 
outbreak, widening the case definition, or screening all HCWs 
irrespective of symptoms, may be of benefit. 
Introduction 
On 31st December 2019, a cluster of undiagnosed pneumonia
cases was reported in Wuhan, China. The causative virus, SARS-
CoV-2, was identified in January 2020, and rapidly spread through
China and across the globe. By 5th June 2020, there were six and a
half million (6535,354) confirmed cases of 2019 novel coronavirus
disease (COVID-19). 1 
Although HCWs in the UK do not appear to be at increased
risk of dying from COVID-19, 2 health and social care workers in
patient-facing or resident-facing roles appear to have higher rates
of infection; between 26 April and 30 May 2020, 1.87% tested
positive for COVID-19 (95% CI: 1.07% −3.02%), compared to 0.32%
(95% CI: 0.26% to 0.44%) of those of working age and not in such
roles. 3 Screening of symptomatic staff in two NHS Trusts (Sheffield
and Newcastle) in March 2020 demonstrated SARS-CoV-2 positiv-
ity rates of 14% and 18%. 4 , 5 Significant nosocomial transmission has
also been shown in a hospital in China. 6 As local community trans-
mission rates fall, nosocomial infection of inpatients and HCWs
will likely be of increasing relative importance than infection im-
ported from the community. 7 In the UK, the proportion of hospi-
talised COVID-19 patients who developed symptoms 7 days afterdmission (average incubation period 5–6 days 8 ) has been increas-
ng, reaching 20% in May 2020. 9 
Estimates of the proportion of general COVID-19 cases that are
symptomatic range from 5 to 80%, 10 with one systematic re-
iew estimating the upper bound of asymptomatic infection to
e 29%. 11 The contribution and mechanisms of asymptomatic and
re-symptomatic transmission remain unclear. Serial throat swab-
ampling of Chinese COVID-19 patients suggested the infectious
eak to be either prior to or at the time of symptom onset. 12 
A London hospital study found HCW prevalence to decrease
rom 7.1% to 1.1% over a five-week period from late March 2020;
o symptoms in the week preceding or following the test were
eported by around a quarter (27%) of HCWs testing positive. 13 
creening of East of England HCWs in April 2020 found a 3.0%
revalence, with 40% of PCR-positive HCWs reporting previous
ymptoms (at least 7 days prior to testing.) 14 Viral loads were sig-
ificantly higher in symptomatic HCWs excluded from, compared
o those remaining at, work. Screening in a Midlands hospital, also
n April, reported a prevalence of 2.4%; a quarter had previous
ymptoms. 15 
To inform the design of HCW screening programmes, we aimed
o ascertain a snapshot of the proportion of working hospital staff
n whom SARS-CoV-2 could be detected, how this relates to ex-
osure histories and reported symptoms prior to sampling, and if
irus could be isolated from PCR-positive samples, indicating in-
reased onward risk of infection to others. 
ethods 
tudy design, setting and participants 
For this prospective, cross-sectional, multi-centre study per-
ormed as a public health investigation as part of Public Health
ngland’s national incident response to COVID-19, staff from six
ospitals were invited to participate from 24th April 2020 to 7th
ay 2020. Ethics approval (NR0202) was obtained from the PHE
esearch Support and Governance Office prior to commencement
nd for all protocol changes. 
The hospitals selected were a convenience sample located in
ondon and north and south England, encompassing five NHS
rusts and one an independent hospital with a charitable hospice. 
Swabbing occurred at each site over one to two days. All staff
adres present on the day of testing were eligible to participate.
ocal site investigators visited different hospital areas to recruit
CWs from a range of job roles. 
Staff who volunteered to participate provided informed con-
ent and were allocated a unique identifier. For the first four sites,
he protocol prescribed full anonymisation; participants were con-
ented not to be given their results and each participant’s unique
dentifier was recorded on the specimen and questionnaire, but
ot linked to any personally identifiable information and was not
ecorded on the consent form, nor revealed to the participant. Full-
nonymisation was based upon the lack of consensus regarding
he significance of the detection of viral RNA in a HCW not meet-
ng the national case definition, how such cases and their contacts
hould be managed, and to allow staff participation without con-
ern of reporting symptoms. 
For the latter two sites, participants provided consent to be
iven positive and negative results by their respective employers;
his approved protocol amendment change reflected an emerging
ational consensus around recommendations for testing asymp-
omatic NHS hospital staff. Staff with positive PCR results were ad-
ised according to local policies. The unique participant number
as recorded on the consent form, kept by the local site, to al-
ow positive results to be matched and reported to participants.
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Table 1 
Staff demographics. 
Demographics Hospitals 
Total number of staff swabbed A100 B ̂ 200 C211 D207 E226 F208 Total 1152 
Age 
median; 
IQR 
(missing) 
39; 
23–67 
(-) 
40; 
20–65 ( 18 ) 
43; 
19–67 ( 1 ) 
36; 
19–65 ( 5 ) 
40 
(20–68) ( 4 ) 
35 
(20–65) ( 5 ) 
39 
(19–68) ( 32 ) 
Ethnicity 
% BAME (#, missing) 41% 
(40, 2 ) 
12% 
(22, 18 ) 
14% 
30, 1 
41% 
85, 1 
42% 
93, 2 
42% 
86, 2 
32% 
356 26 
Gender 
% Female (#, missing) 71% 
(71, -) 
72% 
(132, 16 ) 
76% 
(159, 1 ) 
68% 
(139, 4 ) 
64% 
(143, 3 ) 
70% 
(145, -) 
70% 
(789, 24 ) 
Clinical facing role 
% Staff (#, missing) 97% 
(96, 1 ) 
78% 
(141, 20 ) 
98% 
(201, 6 ) 
90% 
(179, 9 ) 
92% 
(206, 7 ) 
100% 
(202, 5 ) 
93% 
(1025, 44 ) 
% Job involving AGPs (#, missing) 36% 
(33, 7 ) 
27% 
(48, 19 ) 
33% 
(68, 4 ) 
32% 
(65, 5 ) 
44% 
(95, 10 ) 
52% 
(103, 9 ) 
38% 
(412, 54 ) 
Occupation 
% Nurse (#) 47% 
(46) 
26% 
(47) 
38% 
(80) 
22% 
(43) 
30% 
(67) 
27% 
(55) 
30% 
(338) 
% Doctor (#) 7% 
(7) 
11% 
(24) 
19% 
(41) 
26% 
(51) 
14% 
(32) 
31% 
(64) 
20% 
(219) 
% Occupational & Physiotherapist (#) 4% 
(4) 
9% 
(17) 
– 5% 
(9) 
14% 
(31) 
6% 
(13) 
7% 
(74) 
% Other allied clinical staff (#) 10% 
(9) 
9% 
(19) 
3% 
(7) 
6% 
(11) 
8% 
(18) 
2% 
(4) 
6% 
(69) 
% Cleaner (#) 8% 
(8) 
5% 
(9) 
6% 
(16) 
4% 
(8) 
6% 
(13) 
6% 
(13) 
6% 
(67) 
% Pharmacy (#) 8% 
(8) 
7% 
(13) 
1% 
(3) 
15% 
(29) 
4% 
(9) 
0% 
(1) 
6% 
(63) 
% HCA (#) 2% 
(2) 
3% 
(5) 
5% 
(10) 
5% 
(9) 
5% 
(12) 
7% 
(15) 
5% 
(53) 
% Other ∗ (#) (missing) 13% 
(13) 
27% 
(49) 
26% 
(54) 
20% 
(38) 
19% 
(43) 
19% 
(38) 
21% 
(235) 
( 2 ) ( 17 ) ( 7 ) ( 9 ) ( 1 ) ( 5 ) ( 34 ) 
Workplace setting 
% A&E (#) – 8% 
(15) 
1% 
(2) 
11% 
(22) 
– 14% 
(29) 
6% 
(68) 
% ICU (#) 3% 
(3) 
4% 
(7) 
1% 
(3) 
13% 
(27) 
3% 
(7) 
11% 
(22) 
6% 
(69) 
% COVID-19 ward (#) 23% 
(23) 
14% 
(27) 
16% 
(33) 
20% 
(42) 
15% 
(35) 
31% 
(65) 
20% 
(225) 
% Mixed (only above) (#) – 5% 
(8) 
3% 
(6) 
7% 
(14) 
– 8% 
(16) 
4% 
(44) 
Other ∗∗ (#) (missing) 74% 
(73) 
67% 
(114) 
79% 
(165) 
47% 
(93) 
80% 
(171) 
34% 
(7) 
63% 
(686) 
(1) (29) (2) (9) (13) (6) (60) 
^ 15 forms missing from Hospital B (one batch of samples had 14 forms for 15 samples); results included for testing, proportions calculated excluding missing variables. 
∗ Occupations > 5% listed, other encompasses porters, administration (clinical and other), estates, catering, procurement, manager, maternity, radiology, mixed professions, 
and others. 
∗∗ Other includes maternity, variety of medical and surgical wards, admissions, dispensaries, outpatients, and theatres – preliminary recode analysis suggested the highest 
of the others (AMU, theatres) was less than 5%. 
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i  t two sites, asymptomatic participants with positive PCR results
ere also followed up to monitor for development of symptoms. 
rocedures 
Each participant was asked to complete a one-page question-
aire requesting information about demographics; job role and
rea of work; whether this involves aerosol generating procedures;
ersonal and household symptom history in the past month, cur-
ent symptoms, seasonal allergy symptoms; previous testing for
ARS-CoV-2 and exposures to confirmed or suspected COVID-19
ases without PPE either at work or in the community (see Ap-
endix 1). Responses were subsequently entered into a database
y Public Health England (PHE) staff. 
A combined viral throat and nose swab was taken from each
articipant by experienced staff and placed in viral transport
edium, respecting local Trust infection prevention and control
nd PPE requirements. These were transferred to the laboratoryn the same day for detection of SARS-CoV-2 RNA by real-time
everse transcription Polymerase Chain Reaction (PCR) at the PHE
ational reference laboratory (five hospitals) or one hospital labo-
atory. The PHE laboratory used an Applied Biosystems 7500 FAST
ystem targeting a conserved region of the SARS-CoV-2 open read-
ng frame (ORF1ab) gene. The hospital laboratory used a CE-IVD
it GeneFinder TM COVID-19 Plus RealAmp Kit by OSANGHealtcare,
n the ELITe InGenius R © platform, targeting 3 SARS-CoV-2 genes
RdRp, E, and N). Both PCRs had internal controls. Viral culture
f PHE laboratory positives was attempted in Vero E6 cells with
irus detection confirmed by cytopathic effect up to 14 days post-
noculation. 
tudy size 
A sample size calculation estimated 98 staff would require test-
ng to detect a 10% prevalence (based upon unpublished data in
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Fig. 1. Proportion of individuals reporting symptoms in the last month by SARS-CoV-2 PCR status and symptom 
∗ 438 people reported symptoms within the last month, including two of the three HCW who did not have a swab sent, therefore 436 in total are presented in this figure. 
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c  early to mid-April 2020 shared through professional networks)
with a margin of error 5% (with 90% power). 
Statistical analysis 
Data was cleaned, with rules and changes agreed between two
investigators. Stata (version 15, StataCorp, Texas) was used to de-
scribe the data and a random effects regression analysis was per-
formed to examine the relationship between positive results and
demographics and a priori exposures that were thought predictive
of infection. Variables with p ≤ 0.1 in univariate analyses were in-
cluded in random effects multivariate model. 
Role of the funding source 
The study was funded and undertaken by PHE as part of pan-
demic surveillance. The corresponding author had full access to all
study data and takes final responsibility for submission. 
Results 
Demographics 
Across the 6 sites, a total of 1152 staff were recruited. Partici-
pants included clinical and support staff working in various loca-
tions across the sites, representing a diverse range of job roles. De-
mographics are presented in Table 1 . Almost all (93%) stated that
they worked in a patient-facing environment; 20% worked directly
on COVID-19 wards; and 38% said their work involved perform-
ing aerosol generating procedures (AGPs). The top five groups of
staff included were nurses (30%), doctors (20%), occupational ther-
apists and physiotherapists (7%), other allied clinical staff (6%) and
cleaners (6%). Seventy percent of participants were female. The
median age was 39 years (range 19–68 years old) and one-third32%) reported that they were from black, Asian and minority eth-
ic (BAME) backgrounds. 
ymptoms, prior testing and exposures 
438 (39%) of all participants who answered the questions about
ymptoms (1125), had experienced at least one respiratory, gas-
rointestinal or influenza-like symptom in the previous month (see
ig. 1 ). Of those, half (50%) reported symptoms in keeping with
he national COVID-19 case definition ( Table 2 details staff illness,
ymptoms, and exposures). Among the 426 with a test result avail-
ble, headache, cough and sore throat were common across those
ho tested positive and negative (53% vs 52%; 53% vs 42%; and
3% vs 42%). Myalgia, anosmia, change in taste and fever were
arkedly more common in HCWs who tested positive (60% vs
9%, Fisher’s Exact p = 0.019; 53% vs 19%, p = 0.004; 47% vs 17%,
 = 0.008; 47% vs 24%, p = 0.056). Runny nose was more common
n those who tested negative (20% versus 58%, p = 0.185) Table 3 . 
One in four of all participants (25%) reporting symptoms in the
ast month still had symptoms on the day of sampling. We did not
sk explicitly what these symptoms were, however 47% of those
ith current symptoms reported that they had experienced at least
ne of cough or fever in the past month. One in ten (12%) reported
 household member with a respiratory illness in the past month. 
Nearly four in ten (39%) reported seasonal respiratory allergies;
here was an association between those reporting symptoms in the
ast month and presence of seasonal allergies (44% [188] versus
6% [234], χ2 p = 0.006). 
10% of participants who answered had been tested for SARS-
oV-2 previously, one quarter (26%) of whom had tested positive.
his was similar for testing within their household (12% of those
ho answered had been tested, with 29% positivity). 
One third of all participants (34%) reported an exposure to
OVID-19 without appropriate PPE in the hospital, and this was
onsistent across hospital sites (range 23–42%). 4% had experienced
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Table 2 
Staff illness, symptoms, and exposures. 
Illness Hospitals 
Total number ofstaff swabbed A100 B ̂ 200 C211 D207 E226 F208 Total1152 
Symptoms 
% Last month (number, missing Ω ) 38% 
(38, 1 ) 
42% 
(77, 15 ) 
35% 
(73, 3 ) 
49% 
(101, 1 ) 
28% 
(63, 1 ) 
43% 
(86, 6 ) 
39% 
(438, 27 ) 
% Symptomatic with fever and/or cough (#) 58% 
(21) 
41% 
(32) 
36% 
(26) 
55% 
(56) 
65% 
(41) 
51% 
(44) 
50% 
(220) 
% Current symptoms ∗ (#, missing) 31% 
(11, 2 ) 
26% 
(19, 5 ) 
28% 
(19, 5 ) 
22% 
(22, 1 ) 
22% 
(13, 3 ) 
24% 
(19, 7 ) 
25% 
(103 , 23 ) 
% Current with fever and/or cough ∗∗ (#) 73% 
(8) 
32% 
(6) 
21% 
(4) 
45% 
(10) 
62% 
(8) 
63% 
(12) 
47% 
(55) 
SARS-CoV-2 testing 
% Previously tested (#, missing Ω ) α 6% 
(5, 21 ) 
6% 
(8, 89 ) 
12% 
(15, 88 ) 
12% 
(18, 63 ) 
8% 
(10, 103 ) 
11% 
(17, 54 ) 
10% 
(71, 420 ) 
% Tested positive β (#, missing) 20% 
(1, -) 
25% 
(2, -) 
21% 
(3, 1 ) 
22% 
(4, -) 
40% 
(4, -) 
31% 
(5, 1 ) 
26% 
(19, 2) 
Household Illness 
% Respiratory symptoms last month (#, missing) 12% 
(12, 1 ) 
9% 
(17, 17 ) 
8% 
(16, 2 ) 
14% 
(29, 4 ) 
15% 
(34, 2 ) 
13% 
(12, 1 ) 
12% 
(134, 29 ) 
% Previously tested α (#, missing) 4% 
(4, 57 ) 
11% 
(8, 142 ) 
20% 
(11, 156 ) 
9% 
(6, 139 ) 
11% 
(9, 142 ) 
11% 
(14, 131 ) 
12% 
(47, 769 ) 
% Tested positive β (#, missing) 25% 
(1, -) 
0% 
(0, -) 
20% 
(2, 1 ) 
33% 
(2, 1 ) 
38% 
(3, 1 ) 
56% 
(5, 5 ) 
29% 
(13, 8 ) 
Seasonal symptoms 
% Usual hayfever (#, missing) 43% 
(42, 3 ) 
41% 
(73, 37 ) 
40% 
(83, 39 ) 
40% 
(80, 39 ) 
36% 
(78, 35 ) 
39% 
(78, 38 ) 
39% 
(434, 52 ) 
Exposure without PPE 
% No exposure (#) 49% 
(47) 
75% 
(133) 
75% 
(158) 
55% 
(112) 
57% 
(108) 
56% 
(112) 
62% 
(670) 
% Community exposure (#) 13% 
(12) 
2% 
(3) 
2% 
(5) 
4% 
(9) 
6% 
(11) 
2% 
(5) 
4% 
(45) 
% Workplace exposure (#, missing) 39% 
(37) 
23% 
(41) 
23% 
(48) 
40% 
(82) 
37% 
(71) 
42% 
(84) 
34% 
(363) 
(4) (23) (-) (4) (36) (7) (74) 
^ 15 forms missing from Hospital B (one batch of samples had 14 forms for 15 samples); results included for testing, proportions calculated excluding missing variables. 
∗ Percentage of those who answered if they had symptoms within last month. 
∗∗ Fever and cough initially reported, for those who reported current symptoms unclear if these are present. 
α Percentage of those who answered, likely influenced by presence of symptoms (but not completely). 
β Percentage of those who have reported a previous test. 
Ω Or unclear e.g. ticked no symptoms within last month and then ticked individual symptoms. 
a  
p  
r
T
 
C  
t  
s
 
(  
R  
w  
w  
w  
f
 
a  
w  
p  
f  
t  
e  
t  
t  
t
 
l  
3  
T
 
t  
d  
p  
r  
m  
h  
w
D
I
 
a  
r  
e  
l  
A  
i  
s  
t  
s  
a  n exposure in the community, and around one in eight (13%) of all
articipants had a household member who had been unwell with
espiratory symptoms in the past month. 
esting 
Twenty-three out of 1152 staff (2.0%) tested positive for SARS-
oV-2. For three enrolled participants no sample was received in
he laboratory. Test positivity ranged from 0% to 3.9% across the
ites. 
Ct values ranged from 26.2 to 39.3, with a median of 35.7
IQR:32.42–37.57, lower Ct values indicate larger amounts of viral
NA). Viral culture was completed for all nineteen samples that
ere PCR positive in the central PHE laboratory. SARS-CoV-2 virus
as isolated from only one sample (with a Ct value of 26.2); this
as one of 15 samples unable to be matched to a questionnaire
rom one site. 
Amongst the PCR positive participants, there was one missing
nd one incomplete questionnaire. Of those testing positive and for
hom data were available, seventeen (74% of all positive partici-
ants) had experienced previous symptoms, with a median time
rom end of symptoms to sampling of 27 days (range 3–43). Thir-
een (68% of all 19 participants reporting symptoms) had experi-
nced symptoms compatible with the national case definition at
he time for COVID-19 i.e. cough or fever. Five (22%) disclosed that
hey had a previous test, and of these four (17%) had tested posi-
ive. In regression analysis, staff reporting previous symptoms in the
ast month had markedly increased odds of testing positive (aOR
.31, 95%CI 1.33–8.26; p = 0.008), adjusted for age and gender (see
able 4 ). 
Only two participants who tested positive were symptomatic on
he day of testing; one had experienced isolated anosmia for seven
ays and had previously tested SARS-CoV-2 negative, one had ex-
erienced multiple symptoms (including cough and anosmia) and
emained off work for 14 days, and had isolated sore throat re-
aining on testing 28 days after symptom onset. Four staff who
ad no clinical symptoms either prior to or at the time of testing
ere followed-up over the next week; none developed symptoms. 
iscussion 
nterpretation of results 
We found relatively low rates of SARS-CoV-2 carriage in HCWs
t work; 2.0% across all sites (95% CI 1.3–3.0), with prevalence
anging from 0% to 3.9%. This is in keeping with other UK hospital
stimates from a similar time period (one study identified by our
iterature review found prevalence to fall from 4.9% to 1.1% over
pril, 13 and the other studies falling within this range). 14 , 15 This
s eight-fold higher than the general population (0.24%) during a
imilar time-period, 16 and likely higher due to additional symp-
omatic HCWs self-isolating, though this snap-shot coincided with
teep reductions in COVID-19 incidence. 17 The observed differences
cross sites likely arise from differing community prevalence, hos-
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Table 3 
Laboratory results and follow-up. 
Results Hospitals 
Total number ofstaff with swabs A98 B200 C211 D207 E226 F207 Total1149 
SARS-CoV-2 testing 
Date sampled 07/05/20 30/04/20–
01/05/20 
04/05/20–
05/05/20 
24/04/20 29/04/20 07/05/20 –
Number positive (#) 3 
( 2 ) 
3 
(-) 
4 
(-) 
5 
(-) 
0 
(-) 
8 
( 1 ) 
23 
( 3 ) 
Carriage prevalence 
(95%CI) 
1.9% (0.6–8.7) 2.4% 
(0.3–4.3) 
1.9% 
(0.5–4.8) 
2.4% 
(0.8–5.5) 
0% 
(0.0–3.8) 
3.9% 
(1.7–7.5) 
2.0% 
(1.3–3.0) 
Virology 
Ct value median 
(range) 
35.7 
(32.9–36.2) 
37.6 
(26.2–39.3) 
36.8 
(36.0–38.3) 
32.4 
(30.0–37.8) 
– 35.0 
(28.2–38.1) 
35.7 
(26.2–39.3) 
Culture positivity α 0 1 0 0 – 0 1 (5%) 
Symptom status 
a. Post-symptomatic 33% (1) β 67% (2) Ω 75% (3) 80% (4) – 88% (7) 74% (17) 
% Fever or cough (#) 0% (0) 100% (2) 100% (3) 25% (1) – 86% (6) 71% (12) 
% Only other symptoms 100% (1) – – 75% (3) – 14% (1) 28% (5) 
(#, list) Headache – – Myalgia 
Anosmia 
Headache 
Fatigue 
Abdo- pain 
Nausea 
– Sore throat 
Sneezing 
Runny nose 
Days since end of symptom (median, 
range) 
23 
(23) 
12 
(12–12) 
28 
(27–43) 
24 
(17–33) 
– 33 
(3–38) 
27 
(3–43) 
b.% Symptomatic (#) 33% (1) – – 20% (1) – - € 9% (2) 
% Fever or cough (#) 100% (1) – – 0% (0) – – 50% (1) 
(Current symptoms list) Sore throat – – Anosmia – –
c.% Pre/Asymptomatic (#) 33% (1) – 25% (1) – 13% (1) 13% (3) 
Developed symptoms 0 N/A N/A N/A – 0 0 
d. Unknown – 33% (1) – – – – 6% (1) 
∗The three PCR positive staff were excluded – the only staff member with no previous symptoms did not develop symptoms in their 7-day follow-up, of the other two with 
clear COVID-19 history, on continued to have a sore throat (1) and one developed a one-off return of fever (1), and both also had detectable anti-COVID-19 IgG. 
α The 19 positive tests at the central reference laboratory were cultured. 
β One staff member said current symptoms but also stated a definite end date to symptoms 15 days prior. 
Ω One of the positive results was within the 15 samples with no matched questionnaire (Ct value 26.16), one stated their symptoms lasted 2 days but did not finish the 
questionnaire so no answer to whether they were currently symptomatic (Ct value 39.29) – they were assumed to be post-symptomatic. 
€ There were 4 staff who ticked the ‘currently symptomatic’ box in addition to having resolved previous symptoms; on detailed follow-up there were 6 members of 
staff who reported a classic COVID-19 like illness with clear onset date in the previous 7 weeks and no current symptoms, one HCW with previous upper respiratory tract 
infection symptoms and one with no symptoms, the latter two were excluded from work. 
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pital transmission rates, infection prevention and control measures,
and small individual numbers. The one hospital with no positive
HCWs was a ‘clean’ specialist referral centre with no emergency
COVID-19 admissions. 
PCR testing detects viral RNA and positivity does not necessar-
ily indicate infectious virus. Those with mild or asymptomatic in-
fection may be less infectious than those with respiratory symp-
toms, given the commonly accepted natural transmission routes
for COVID-19 (respiratory droplet and direct and indirect contact
routes). 18 Those who remain SARS-CoV-2 positive on testing af-
ter resolution of symptoms i.e. people on the tail end of PCR
positivity, will not necessarily be infectious. Viral RNA shedding
has been reported up to 49–60 days after onset of illness, 19 , 20 
whereas the longest duration of detection of culturable virus is
8–9 days. 21 , 22 
The Ct values of 23 staff who tested SARS-CoV-2 positive in our
study suggest the majority had a low viral load and were unlikely
to be infectious at time of testing (see Supplement S1). SARS-CoV-
2 virus was isolated only from the sample with the lowest Ct value
(26.2); this mirrors a Canadian study where SARS-CoV-2 was only
cultured from 90 samples where the Ct value was less than 24. 23 
Modelling from April 2020 predicted that if both asymptomatic
and symptomatic HCWs were screened and isolated, transmission
could be further reduced by one third (depending on timeliness
of results). 18 Only four HCWs in this cohort had detectable viral
RNA without reporting either current or previous symptoms (0.3%),
implying that rates of asymptomatic or pre-symptomatic COVID-19nfections were low. Therefore, the impact of mass HCW screening
ould be reduced, and we suggest that current prevalence esti-
ates from surveillance data should inform when to institute HCW
creening programmes. 
Five (22%) of 23 positive HCWs experienced symptoms not
n the national case definition; the national case definition was
mended on May 18th 2020 to include a loss or change in sense
f smell or taste, however three cases (13%) complained only of
yalgia, fatigue, headache and gastro-intestinal symptoms, assum-
ng they accurately recalled symptoms. During times of higher
revalence, such as in a hospital outbreak, the number of such
ases would be higher and using a broader case HCW definition
ould capture more cases; this would need to be weighed against
esource implications and risks associated with false positives in
ower prevalence settings. 24 As we enter summer, the prevalence
f other non-COVID respiratory illnesses is lower, and the predic-
ive value of milder symptoms may increase, though this could be
ffset by hayfe ver pre valence. We found a strong association with
yalgia and a positive test – this was among the most reported
ymptoms (57%) in a French case series of nearly 1500 patients af-
er fever and cough, 25 though was much less common in a large
K study of over 20,0 0 0 inpatients ( ∼20%). 26 
One third of participants reported an exposure without appro-
riate PPE in the hospital setting, though we did not capture the
etails of these such as PPE breaches or inadvertent exposures to
CWs or patients. It is not possible to infer whether acquisition
as community or nosocomial. 
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Table 4 
Random effects regression analysis. 
Univariate analysis 
Multivariate analysis(with age and 
gender) 
Proportion positive(#/23, 
missing Ω ) 
Proportion ∗
negative (#/1126, 
missing Ω ) Odds Ratio (95% CI) a p value a 
Odds Ratio (95% CI) 
a p value a 
Age (mean) 41.2 
( 1 ) 
39.9 
( 32 ) 1.%2 (0.98–1.05) per 
increasing year 
0.456 1.02 (0.98–1.06) 0.328 
Gender (female) 36% 
(8, 1 ) 
30% 
(331, 23 ) 
0.73 (0.30–1.78) 
for females 
0.494 0.57 (0.28–1.65) 0.389 
Ethnicity (BAME) 32% 
(7, 1 ) 
32% 
(348, 25 ) 
0.96 (0.38–2.42) 
for non-BAME staff
0.921 
Clinical role 90% 
(18, 3 ) 
93% 
(81, 41 ) 
1.99 (0.41–9.72) 
for non-clinical jobs 
0.396 
Perform AGPs 42% 
(8, 4 ) 
37% 
(403, 49 ) 
0.86 (0.34–2.18) 
for not performing AGPs 
0.750 
Symptoms in 
last month 
68% 
(15, 1 ) 
38% 
(421, 16 ) 
3.31 (1.33–8.26) 
for those with symptoms 
last month 
0.010 3.46 (1.38–8.67) 0.008 
Case definition 
symptoms 
66% 
(10, 0 ) 
50% 
(170, 0 ) 
2.01 (0.67–5.98) if fever 
and/or cough 
0.210 
Seasonal 
allergies 
29% 
(6, 2 ) 
40% 
(426, 50 ) 
1.67 (0.64–4.34) 
for those who do not have 
allergies 
0.296 
Current 
symptoms α
21% 
(3, 1 ) 
25% 
(100, 21 ) 
0.82 (0.22–2.99) 
for those with current 
symptoms 
0.762 
Household symptoms 19% 
(4, 2 ) 
14% 
(146, 58 ) 
1.26 (0.47–3.37) 
for those with 
symptomatic households 
0.639 
Work exposure (with 
no PPE) β
35% 
(7, 3 ) 
34% 
(356, 71 ) 
1.08 (0.42–2.76) 
for healthcare exposures 
0.881 
∗ Unless stated otherwise. 
α Percentage of those who answered if they had symptoms within past month. 
a p values calculated using Wald tests, odds ratios calculated by logistic regression employing random effects. 
β No positives with community exposure. 
Ω Or unclear e.g. ticked no symptoms within last month and then ticked individual symptoms. 
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s  trengths and limitations 
This study is the first which estimates point prevalence of
ARS-CoV-2 carriage in HCWs at work in multiple job roles across
 number of hospitals in different UK regions. Our study also
ncludes a larger number of participants than previous reported
tudies. Prevalence among HCWs will be dynamic, and likely to
hange as the infection rate across the whole population falls. 13 
his snapshot study is unable to capture such trends. 
Selection bias could be present in either direction, particularly
or the latter two sites: staff may have been more inclined to vol-
nteer if they were concerned about COVID-19 infection, or less
ikely if they were anxious of work exclusion for themselves or
heir household. Staff with symptoms or exposures may have been
ess inclined to report these honestly (information bias), though
eassurance about confidentiality will have at least in part mit-
gated this. The potential for symptom and exposure recall bias
bout was present throughout, and questionnaires were single data
ntered. 
Due to full anonymisation we were unable to follow-up one
articipant who was asymptomatic at the time of testing to see if
hey developed symptoms, and the one culture positive participant
as unable to be matched to a questionnaire, so it is not possi-
le to estimate the true asymptomatic infection prevalence. Of the
7 post-symptomatic HCWs, four had a previous positive test re-
ult, and a further six were followed-up at the two latter hospital
ites; the remaining seven were assumed to be post-symptomatic
all but one had fever, cough or anosmia). t  onclusion 
Although the point-prevalence of SARS-CoV-2 RNA detection is
igher for our HCW population than for the general population,
he majority of HCWs identified were unlikely to be infectious
t the time of testing, based on Ct values, viral culture results
nd symptom history. Testing for SARS-CoV-2 in HCWs who meet
he current national case definition of cough, fever or change in
ense of taste or smell may not capture all positive cases. Screen-
ng HCWs based on a broader case definition, or whilst asymp-
omatic in certain situations, may be more beneficial when com-
unity prevalence is rising or high; however screening should bal-
nce the benefit of identifying additional cases against the resource
mplications and the risk of excluding staff who are not infectious.
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